Early Empagliflozin Doesn't Curb HF Hospitalizations, Deaths Post-MI: EMPACT-MI
(UPDATED) Neutral findings for another SGLT2 inhibitor, after the “soft” success of DAPA-MI, are a rare disappointment for this class.
Source: tctmd.com
Stay updated with breaking news from Dphil Brigham. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
(UPDATED) Neutral findings for another SGLT2 inhibitor, after the “soft” success of DAPA-MI, are a rare disappointment for this class.
Artificial intelligence tools are already changing scientific publishing, but oversight is questionable and concerns abound.
For less-sick patients, results from the ACT trials showed no benefits with colchicine, aspirin, or rivaroxaban plus aspirin.